IMV Inc IMVIF Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.00 up $0.00, 10,000.00% at close Nov 5
Last close · Previous close $0.00
- Market cap
- At the Nov 5 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.00up $0.00, 9,900.00%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.00Nov 4
- Volume1.00Nov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume155.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.00 to $0.00; now $0.00
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
IMVIF beat the S&P 500 in 4 of 6 periods.
| Period | IMVIF and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IMVIF: up 9,900.0% S&P 500: down 5.4% | IMVIF beat the S&P 500 by 9,905.4 percentage points Beat |
| 3M | IMVIF: unchanged S&P 500: down 4.5% | IMVIF beat the S&P 500 by 4.5 percentage points Beat |
| YTD | IMVIF: up 9,900.0% S&P 500: up 8.3% | IMVIF beat the S&P 500 by 9,891.7 percentage points Beat |
| 1Y | IMVIF: up 9,900.0% S&P 500: up 9.3% | IMVIF beat the S&P 500 by 9,890.7 percentage points Beat |
| Long term | ||
| 3Y | IMVIF: down 98.9% S&P 500: up 74.8% −77.8% vs +20.5% a year | IMVIF trailed the S&P 500 by 173.7 percentage points Trailed |
| 5Y | IMVIF: down 100.0% S&P 500: up 67.3% −91.0% vs +10.8% a year | IMVIF trailed the S&P 500 by 167.3 percentage points Trailed |
$10,000 invested in IMVIF 5 years ago (Nov 5, 2021) would be worth about $0 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,730.
IMVIF beat the S&P 500 in 4 of 6 periods.
| Period | IMVIF and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IMVIF: up 9,900.0% S&P 500: down 5.4% | IMVIF beat the S&P 500 by 9,905.4 percentage points Beat |
| 3M | IMVIF: unchanged S&P 500: down 4.8% | IMVIF beat the S&P 500 by 4.8 percentage points Beat |
| YTD | IMVIF: up 9,900.0% S&P 500: up 7.5% | IMVIF beat the S&P 500 by 9,892.5 percentage points Beat |
| 1Y | IMVIF: up 9,900.0% S&P 500: up 8.2% | IMVIF beat the S&P 500 by 9,891.8 percentage points Beat |
| Long term | ||
| 3Y | IMVIF: down 98.9% S&P 500: up 68.6% −77.8% vs +19.0% a year | IMVIF trailed the S&P 500 by 167.5 percentage points Trailed |
| 5Y | IMVIF: down 100.0% S&P 500: up 56.4% −91.0% vs +9.4% a year | IMVIF trailed the S&P 500 by 156.4 percentage points Trailed |
$10,000 invested in IMVIF 5 years ago (Nov 5, 2021) would be worth about $0 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,645.
All-time high
$68.80
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Jun 1, 2018.
Stock splits
1
1-for-10 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY22, the quarter ended Dec 31, 2022. “Last 12 months” means the four quarters from Jan 1, 2022 to Dec 31, 2022, and balance-sheet figures are as of Dec 31, 2022.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $246.48Kup 65.3%
- Net income
- −$29.10M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q1 FY21 (Mar 31, 2021) | $55.65K | −$5.61M | Paused See the note under the price. |
| Q2 FY21 (Jun 30, 2021) | $33.87K | −$6.00M | Paused See the note under the price. |
| Q3 FY21 (Sep 30, 2021) | $32.28K | −$8.22M | Paused See the note under the price. |
| Q4 FY21 (Dec 31, 2021) | $27.34K | −$9.17M | Paused See the note under the price. |
| Q1 FY22 (Mar 31, 2022) | $19.05K | −$8.35M | Paused See the note under the price. |
| Q2 FY22 (Jun 30, 2022) | $26.36K | −$7.68M | Paused See the note under the price. |
| Q3 FY22 (Sep 30, 2022) | $89.39K | −$6.77M | Paused See the note under the price. |
| Q4 FY22 (Dec 31, 2022) | $111.68K | −$6.30M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $176.47K | −$20.44M | Paused See the note under the price. |
| FY21 (Dec 31, 2021) | $146.88K | −$28.59M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $240.15K | −$27.73M | Paused See the note under the price. |
Margins
- Gross 100.0%
- Operating −11,856.0%
- Net −11,805.0%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- Not reportedLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flowNot reportedLast 12 months
- Capital spendingNot reportedLast 12 months
Shareholder returns
- Not reportedLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $15.49MAs of Dec 31, 2022
Cash plus short- and long-term marketable securities on the Dec 31, 2022 balance sheet.
- Total debt$21.09MAs of Dec 31, 2022
- Net debt$5.60MAs of Dec 31, 2022
- Book value per sharePausedAs of Dec 31, 2022
See the note under the price. - 2.93As of Dec 31, 2022
Current assets divided by current liabilities on the Dec 31, 2022 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −7,489.8%Last 12 months
Over the last 12 months, IMV lost money: its net loss was 7,489.8% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −104.7%Last 12 months
Over the last 12 months, IMV’s net loss was 104.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About IMV Inc
IMV Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapies based on its proprietary drug delivery platform (DPX) to potentially treat different forms of cancer, including, but not limited to DLBCL, breast, advanced ovarian and bladder cancers. IMV’s immunotherapies are being evaluated as a combination therapy in the treatment of some of these cancers as well. Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking information under applicable securities laws. All information that addresses activities or developments that we expect to occur in the future is forward-looking information.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Nova Scotia, Canada
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
IMVIF news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
IMVIF stock FAQ
What is IMVIF stock’s price today?
IMV (IMVIF) traded at $0.00 at the close on , unchanged from the previous close of $0.00. Over the past 52 weeks it has traded between $0.00 and $0.00.
If you invested $1,000 in IMVIF 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in IMVIF on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $100,000 if invested one year ago. Past performance doesn’t predict future returns.
How much revenue does IMV make?
IMV reported $246.5 thousand of revenue over the four quarters to , up 65.3% from the twelve months before. In its latest quarter (Q4 FY22, ended ) revenue was $111.7 thousand, up 308.4% from a year earlier.
Is IMV profitable?
Not over the four quarters to . IMV reported a net loss of $29.1 million across those four quarters on $246.5 thousand of revenue.
Does IMVIF pay a dividend?
IMV hasn’t paid a dividend in the last twelve months.
What is IMVIF’s 52-week high and low?
Over the past 52 weeks IMVIF has traded as low as $0.00 and as high as $0.00. At $0.00 at the close on , it is 95.0% below that high and 9,900.0% above the low.
What is IMVIF’s all-time high?
IMVIF’s highest closing price was $68.80 on , adjusted for stock splits. At $0.00 at the close on , it is 100.0% below that record.
Has IMVIF stock ever split?
Yes, once: 1-for-10 on .
How has IMVIF stock performed?
Including dividends and measured to the close on , IMVIF has returned +9,900.0% so far this year and +9,900.0% over the past year, and −100.0% over five years (−91.0% a year). Over the same periods the S&P 500, measured by SPY, returned +8.3%, +9.3% and +67.3%. Past performance doesn’t predict future returns.
What sector and industry is IMV in?
IMV is in the Healthcare sector and the Biotechnology industry, and is headquartered in Nova Scotia, Canada.
What exchange does IMVIF trade on?
IMV trades on the PINK under the ticker symbol IMVIF. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.